MedTrace Logo

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

NCT06245330 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-02-07

No results posted yet for this study

Summary

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

Conditions

Interventions

DRUG

AST-001

liquid formulation for Intravenous infusion

Sponsors & Collaborators

  • Ascentawits Pharmaceuticals, Ltd

    lead INDUSTRY

Principal Investigators

  • Ying Cheng · Study Principal Investigator

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-07
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06245330 on ClinicalTrials.gov